Premium
Bosutinib Acts as a Tumor Inhibitor via Downregulating Src/NF‐κB/Survivin Expression in HeLa Cells
Author(s) -
Yu Liang,
Guo Weiqiang,
Liu Ling,
Zhang Guoping,
Zhang Fahuang,
Qu Yuan,
Liu Yining,
Li Hui,
Li Huiwu
Publication year - 2019
Publication title -
the anatomical record
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.678
H-Index - 62
eISSN - 1932-8494
pISSN - 1932-8486
DOI - 10.1002/ar.24269
Subject(s) - bosutinib , survivin , cervical cancer , hela , cancer research , proto oncogene tyrosine protein kinase src , tyrosine kinase , cancer , medicine , nf κb , tyrosine kinase inhibitor , apoptosis , chemistry , dasatinib , cell , receptor , biochemistry
Efforts have been made to find effective medical drugs for cervical cancer treatment. The incidence of cervical cancer ranks second among women, and is a serious threat to women's health. Aberrant activation of the nonreceptor protein tyrosine kinases such as Src is commonly observed in progressive stages of human tumors. Thus, targeting Src kinase could be a promising strategy for cervical cancer therapy. In this study, we explored the potential utility of bosutinib in the treatment of cervical cancer. We found that bosutinib, as a potent dual Src/Abl inhibitor, could exert anti‐tumor effects on cervical cancer. Bosutinib inhibited cervical cancer cells proliferation and colony formation ability in a dose‐dependent manner, and also induced apoptosis. Mechanistically, bosutinib effectively decreased the activity of Src/NF‐κB/survivin signaling pathway. Our study provided a biological rationale to test bosutinib as a valuable therapeutic option for cervical cancer patients. Anat Rec, 302:2193–2200, 2019. © 2019 American Association for Anatomy